ARWR · NASDAQ · Biotechnology

Arrowhead Pharmaceuticals (ARWR)

Develops targeted RNAi medicines and markets REDEMPLO for familial chylomicronemia syndrome.

$71.87
After hours+0.04 (+0.06%)
At close$71.83(+4.42%)